公司资料
Merck 股价、新闻与催化剂
- 股票代码:
- MRK
- 交易所:
- NYSE
- 行业:
- Oncology, Immunotherapy, Vaccines
- 所在地:
- United States
股票表现
135.97 USD (+0.10%)
收盘价
最后更新: 2026年8月17日
286B USD
市值
股价为何变动
As of Aug 17, 2026, MRK was little changed and closed at $135.97. No new same-company headline was identified in the current news window.
公司概览
业务概览
Merck is a diversified pharmaceutical company with major exposure to oncology, vaccines, infectious disease, and animal health. The company’s market story still revolves around Keytruda, pipeline replacement, and the durability of its broader portfolio.
所在地与行业分类
Headquartered in the United States and listed on NYSE, Merck has a global pharmaceutical footprint with strong international reach. It sits in large-cap biopharma and not in a narrow biotech niche.
商业模式特征
Merck generates revenue from a mix of blockbuster products, vaccines, and pipeline assets. Investors watch oncology growth, patent lifecycle pressure, vaccine demand, and whether the next wave of products can offset concentration risk.
生物医药行业定位
Merck is a mature large-cap pharma name with meaningful biotech-like catalyst sensitivity around oncology and vaccine updates. It is less volatile than clinical-stage companies, but major pipeline or label events can still move sentiment.
未来催化剂
- Merck’s next three months are likely to focus on Winrevair uptake, oncology execution, and any pipeline readout that helps replace the market’s dependence on Keytruda. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。